In an industry where the stakes are as high as the potential rewards, the spotlight is often on those who dare to innovate. This time, it’s centered on Argenx, a fast-rising pharmaceutical star. The company’s inclusion in the Baron Funds’ third-quarter 2023 investor letter shines a glaring light on its potential as a promising investment […]